A derivative of 3-(1,3-diarylallylidene)oxindoles inhibits dextran sulfate sodium-induced colitis in mice
Pharmacological Reports · 2024
DOI: 10.1007/s43440-024-00616-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacological Reports, 2024. Verfasst von Young-Jin Jeong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences, BK21 FOUR Team for Advanced Program for SmartPharma Leade…. Hauptthemen laut MEDLINE: Dextran Sulfate, Colitis, Oxindoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basic Science Research Program through the National Research Foundation of Korea.
Abstract (Originalsprache)
Background
IA-0130 is a derivative of 3-(1,3-diarylallylidene)oxindoles, which is a selective estrogen receptor modulator (SERM). A previous study demonstrated that SERM exhibits anti-inflammatory effects on colitis by promoting the anti-inflammatory phenotype of monocytes in murine colitis. However, the therapeutic effects of oxindole on colitis remain unknown. Therefore, we evaluated the efficacy of IA-0130 on dextran sulfate sodium (DSS)-induced mouse colitis.
Methods
The DSS-induced colitis mouse model was established by administration of 2.5% DSS for 5 days. Mice were orally administered with IA-0130 (0.01 mg/kg or 0.1 mg/kg) or cyclosporin A (CsA; 30 mg/kg). Body weight, disease activity index score and colon length of mice were calculated and histological features of mouse colonic tissues were analyzed using hematoxylin and eosin staining. The expression of inflammatory cytokines and tight junction (TJ) proteins were analyzed using quantitative real-time PCR and enzyme-linked immunosorbent assay. The expression of interleukin-6 (IL-6) signaling molecules in colonic tissues were investigated using Western blotting and immunohistochemistry (IHC).
Results
IA-0130 (0.1 mg/kg) and CsA (30 mg/kg) prevented colitis symptom, including weight loss, bleeding, colon shortening, and expression of pro-inflammatory cytokines in colon tissues. IA-0130 treatment regulated the mouse intestinal barrier permeability and inhibited abnormal TJ protein expression. IA-0130 down-regulated IL-6 expression and prevented the phosphorylation of signaling molecules in colonic tissues.
Conclusions
This study demonstrated that IA-0130 suppressed colitis progression by inhibiting the gp130 signaling pathway and expression of pro-inflammatory cytokines, and maintaining TJ integrity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences, BK21 FOUR Team for Advanced Program for SmartPharma Leaders, College of Pharmacy, The Catholic University of Korea, NP512, Hall…
- Laboratory of Pharmaceutical Manufacturing Chemistry, Integrated Research Institute of Pharmaceutical Sciences, College of Pharmacy, The Catholic University of Korea, 43 Jibong-Ro, Bucheon‑si, Gyeonggi‑do, 14662, Republ…
Förderung
- Basic Science Research Program through the National Research Foundation of Korea
Zitieren
APA
Jeong, Y. J., Lee, H. R., Park, S. A., Lee, J. W., Kim, L. K., Kim, H. J., Seo, J. H., & Heo, T. H. (2024). A derivative of 3-(1,3-diarylallylidene)oxindoles inhibits dextran sulfate sodium-induced colitis in mice. Pharmacological Reports. https://doi.org/10.1007/s43440-024-00616-2
Vancouver
Jeong YJ, Lee HR, Park SA, Lee JW, Kim LK, Kim HJ, et al. A derivative of 3-(1,3-diarylallylidene)oxindoles inhibits dextran sulfate sodium-induced colitis in mice. Pharmacological Reports. 2024. doi:10.1007/s43440-024-00616-2
BibTeX
@article{Jeong2024,
author = {Jeong, Young-Jin and Lee, Hae-Ri and Park, Sun-Ae and Lee, Joong-Woon and Kim, Lee Kyung and Kim, Hee Jung and Seo, Jae Hong and Heo, Tae-Hwe},
title = {A derivative of 3-(1,3-diarylallylidene)oxindoles inhibits dextran sulfate sodium-induced colitis in mice},
journal = {Pharmacological Reports},
year = {2024},
doi = {10.1007/s43440-024-00616-2}
}
EUVIMED